EGFR and non-small cell lung carcinoma: Another study involving 153 Taiwanese patients concluded that lower pre-treatment PD-L1 was associated with better ORR and PFS in EGFR mutated NSCLC treated with EGFR-TKIS, and patients with PD-L1 TPS ≥50% were more likely had primary resistance to EGFR-TKI (33).